Scientists at the 2nd World Congress on Targeting Longevity in Berlin delivered an uncomfortable verdict in April 2026: despite decades of discoveries, longevity science has stalled on clinical translation. The…
Mitochondrial transplantation, once a fringe idea, is now being tested in human clinical trials for heart failure, stroke, and age-related cellular decline. A new wave of 2026 research shows that…
A landmark 2026 study in Nature Aging reveals that phosphoenolpyruvate (PEP), a glycolytic metabolite, acts as a natural brake on the cGAS-STING inflammatory pathway. As PEP levels decline with age,…
First-generation senolytics like dasatinib plus quercetin showed only subtle effects in human trials. A new generation of senolytic CAR-T cells borrows cancer immunotherapy and retrains it to hunt senescent cells….
At the 2nd World Congress on Targeting Longevity in Berlin, researchers are proposing a paradigm shift: aging is not a collection of molecular defects to be fixed, but a progressive…
For the first time in history, a therapy designed to reverse the cellular age of human tissue is being tested in living patients. Here is what the science actually shows,…
A landmark Nature Aging expert review by 25 scientists, a Science Advances study showing NAD+ reverses Alzheimer’s memory deficits through RNA splicing, and the first human evidence that oral NAD+…
New research from 2025 and 2026 confirms that zone 2 training, the low intensity aerobic exercise most people skip, is the single most effective way to build mitochondrial density, improve…
ARPA-H’s $144 million PROSPR program is testing rapamycin, semaglutide, and dapagliflozin in 726 healthy older adults, funding a first-in-humans trial of a retrotransposon-silencing HIV drug, and building a validated biological…
ARK Invest dumped $87 million in Nvidia and Meta last week and redirected capital into Tempus AI, GeneDx Holdings, CRISPR Therapeutics, and other healthcare AI and genomics companies. The signal…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.